. Author manuscript; available in PMC: 2017 Jul 6.

Published in final edited form as: J Alzheimers Dis. 2016 Jul 6;53(4):1499–1516. doi: 10.3233/JAD-151179

Table 1.

Description and EC₅₀ values of FDA approved drugs obtained from primary and secondary screenings that showed significant enhancement in the barrier function of bEnd3 monolayer.

Drug	Description^a	EC₅₀ (μM)
Beclomethasone	Anti-inflammatory glucocorticoid	0.76
Candesartan	Angiotensin II receptor antagonist	1.17
Pancuronium	Neuromuscular blocking agent; skeletal muscle relaxant	2.24
Etodolac	Non-steroidal anti-inflammatory drug (NSAID)	2.32
Oxaprozin	Non-steroidal anti-inflammatory drug (NSAID)	3.14
Tomoxetine	Norepinephrine reuptake blocker	3.86
Granisetron	Serotonin 5-HT3 receptor antagonist and antiemetic	4.56

Sigma Aldrich Website, http://www.sigmaaldrich.com/chemistry/drug-discovery/validation-libraries/lopac1280-navigator.html.